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S U M M A R Y
Objectives: An outbreak of bacteremia caused by Pseudomonas spp (P. fulva and P. putida) was ﬁrst
identiﬁed in our hospital in the summer of 2010 and reoccurred in the following year. Based on the
epidemiological data collected in these 2 years, we initiated an investigation on the source of the
outbreak. The aim of this study was to report the results of the investigation, as well as the intervention
strategies that resulted in successful control of the outbreak.
Methods: An infection control team was set up consisting of infectious disease specialists,
microbiologists, infection control practitioners, and head nurses. The microbiology and medical records
of case-patients with P. fulva or P. putida bloodstream infections were reviewed. Environmental samples
and intravenous (IV) solutions from the wards and the pharmacy center were collected for culturing. The
molecular characteristics of the bacterial isolates were studied by pulsed-ﬁeld gel electrophoresis
(PFGE). Strict infection control strategies were implemented.
Results: A total of 20 case-patients from ﬁve inpatient wards were identiﬁed during three summer
seasons from 2010 to 2012. Nineteen of them recovered with proper antibiotics. Unfortunately one died
from complications of heart failure. A total of 19 isolates of P. fulva and four of P. putida were identiﬁed, of
which 20 were from blood, two from environmental surface samples from the hospital pharmacy, and
one from an in-use compounded solution from a case-patient in the cardiology ward. Molecular analysis
revealed that the P. fulva isolated from the in-use compounded solution (5% glucose solution containing
insulin, isosorbide dinitrate, and potassium magnesium aspartate) and the environmental samples had
the same PFGE type as the clinical isolates.
Conclusions: The investigation identiﬁed that contaminated IV solution was the source of the P. fulva
bacteremia, which prompted us to implement intensiﬁed control measures that resulted in successful
control of the outbreak.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Pseudomonas fulva is isolated mainly from environmental
sources.1 One report of P. fulva isolation from the sputum of a
patient with cystic ﬁbrosis has been documented in the literature,
however the authors did not report the clinical signiﬁcance of this
ﬁnding.2 The ﬁrst report of a bloodstream infection caused by
P. fulva was reported in South Korea in 2010.3 In addition, P. fulva* Corresponding author. Tel.: +86 010 8523 1513; fax: +86 010 8523 1514.
E-mail address: caobin1999@gmail.com (B. Cao).
http://dx.doi.org/10.1016/j.ijid.2014.02.013
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).was identiﬁed from cerebrospinal ﬂuid culture by Almuzara et al.4
More importantly, this isolate carried the blaVIM-2 gene cassette.
Pseudomonas putida, a low-virulence opportunistic pathogen,
primarily causes nosocomial infection in immunocompromised
patients and in patients with medical devices or catheters.5–7 P.
putida has also been implicated in outbreaks of bacteremia due to
transfusion of contaminated blood or ﬂuid.7,8 Due to their ability to
metabolize a wide range of compounds, members of this species
are able to colonize moist and inanimate environmental surfaces.9
This can serve as a reservoir and cause nosocomial infections.
P. fulva and P. putida have rarely been detected in clinical
specimens at our hospital in the past. However, a number ofciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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recently, mostly in the cardiology ward. We describe herein an
outbreak of 16 cases of P. fulva and four cases of P. putida
bacteremia that occurred in our hospital from August 2010 to
September 2012, with emphasis on the molecular epidemiology of
the outbreak, as well as the intervention strategies that resulted in
successful control of the outbreak.
2. Methods
2.1. Background of the outbreak
The Beijing Chao-Yang Hospital is a 1500-bed, tertiary-care,
academic hospital in Beijing, China. The hospital pharmacy center
routinely prepares various reconstituted solutions for patients
with special needs, which are then distributed to different wards
every day. On September 5, 2012, two patients in the cardiology
ward experienced a sudden onset of fever following intravenous
ﬂuid infusion. Peripheral blood samples that were drawn on site
were sent for microbiological analysis. The next day, Pseudomonas
spp (P. fulva) was recovered from the blood samples of the patients.
Since similar cases had been reported during the summer season
over the past 2 years in the cardiology ward in our hospital, the
Chao-Yang Hospital Department of Infection Control was notiﬁed
on September 7, 2012. An infection control team was set up on the
same day, consisting of infectious diseases physicians, microbiol-
ogists, infection control practitioners, and head nurses from the
hospital. The team members discussed the problems and made
decisions on control measures with the agreement of the hospital
authority, and initiated an investigation within 24 h. A third
patient in the same ward was identiﬁed as having a Pseudomonas
spp (P. fulva) bloodstream infection in the following 5 days.
2.2. Case deﬁnition
Microbiology and medical records were re-examined to identify
patients with Pseudomonas spp (P. fulva or P. putida) bloodstream
infections in the whole hospital. A case patient was deﬁned as any
patient with symptoms and signs consistent with sepsis and a
blood culture positive for Pseudomonas spp (P. fulva or P. putida)
during the period January 1, 2010 to September 30, 2012.
2.3. Infection control strategies implemented
The ﬁrst intervention was the prompt collection and quarantine
of all the intravenous (IV) solutions used by patients in the
cardiology ward, followed by culturing of solution samples in the
clinical microbiology laboratory. At the same time, unopened stock
solutions from the hospital pharmacy center including 0.9% NaCl,
5% glucose, 10% glucose, etc., in their original packaging, were also
cultured. Environmental cultures from the cardiology ward and
hospital pharmacy center were obtained, including samples from
work surfaces, baskets for carrying compounded solutions,
equipment, and door handles. Meanwhile, all health care workers
were informed of the P. fulva bacteremia outbreak through the
hospital’s local internet. Heightened infection control measures,
especially hand hygiene, were enforced. Environmental surfaces in
the cardiology ward were rigorously cleaned twice a day with 5%
sodium hypochlorite throughout the outbreak.
2.4. Identiﬁcation of the isolates
Originally, the organisms were identiﬁed as P. putida (99%
probability) in all of the samples (n = 23) using a phenotypic
identiﬁcation systems, Vitek 2 Compact (bioMe´rieux, France). Then
DNA sequencing analysis was performed using four pairs ofprimers, including 16S rRNA, gyrB, rpoB, and rpoD, as described
previously,3 to further conﬁrm the identity of the isolates.
2.5. Pulsed-ﬁeld gel electrophoresis (PFGE)
PFGE was conducted as described previously, with a slight
modiﬁcation.10 Brieﬂy, whole-cell genomic DNA of culture lysed
cells representing each isolate embedded in 1% agarose plugs (Bio-
Rad, Richmond, CA, USA) were digested with the restriction
enzyme SpeI (TaKaRa Biotechnology, Dalian, China) and separated
by electrophoresis through 1% pulsed-ﬁeld-certiﬁed agarose (Bio-
Rad) using a CHEF-Mapper instrument (Bio-Rad). Electrophoretic
switch times of 4–40 s were used with a 6 V/cm current and a
switch angle of 1208 under a constant temperature of 14 8C. PFGE
patterns were interpreted using the criteria proposed by Tenover
et al.11
2.6. Ethics statement
Permission to use the information in the medical records of the
patients and the P. fulva and P. putida isolates for research purposes
was given by the ethics committee of Beijing Chao-Yang Hospital.
3. Results
3.1. Epidemiological ﬁndings
A list of 20 case-patients from ﬁve wards was identiﬁed using
the microbiology records for the period August 8, 2010 to
September 30, 2012. The clinical features and outcomes of the
20 patients with Pseudomonas spp (P. fulva or P. putida) bacteremia
are summarized in Table 1. Case-patients had been admitted for
various underlying medical conditions, including myocardial
infarction, hypertension, hyperlipidemia, pneumonia, cancer,
diabetes mellitus, anemia, etc., and had been admitted to different
wards: cardiology ward (n = 12), neurosurgery ward (n = 3),
surgery intensive care unit (SICU) (n = 2), gastrointestinal disease
ward (n = 2), and cardiac care unit (CCU) (n = 1). Fifteen (75%)
patients were male. The case-patients had all been administered
medication and/or nutrients and electrolytes via the central or
peripheral vein within 48 h of developing Pseudomonas spp (P. fulva
or P. putida) bacteremia during their hospital stay. Most of the
patients in the cardiology ward had received continuous intrave-
nous infusions for more than 24 h. All the patients received
antimicrobial drugs for the Pseudomonas spp (P. fulva or P. putida)
bloodstream infection. Nineteen out of the 20 (95%) patients
became free of Pseudomonas spp (P. fulva or P. putida) bloodstream
infection and were subsequently discharged from the hospital
without complications from the bacteremia. Unfortunately one
patient (patient 9) died of heart failure.
3.2. Laboratory ﬁndings
Originally, the organisms were identiﬁed as P. putida (99%
probability) using a phenotypic identiﬁcation system, the Vitek 2
Compact (bioMe´rieux, France). DNA sequencing showed 19 out of
23 of the samples to be most closely related to P. fulva (>98%
homology to all four fragments). However, the remaining four
samples showed 95% homology to P. putida (Table 1).
Among the 23 isolates, 20 were from positive clinical samples of
patients in ﬁve wards, two were from environmental surface
samples of the hospital pharmacy, and one was from the used
compounded solution (5% glucose solution containing insulin,
isosorbide dinitrate, and potassium magnesium aspartate) from
patient 18 in the cardiology ward. The two positive environmental
surface samples were isolated from the hospital pharmacy bench
Table 1
Demographic, clinical, and laboratory characteristics of 20 case-patients with Pseudomonas fulva and Pseudomonas putida bloodstream infections after receiving intravenous
treatment during the period August 2010 to September 2012
Case No. Age, gender Ward Medical treatment
prior to culture
Date of
isolation
Antibiotic treatment
following culture
Outcome Isolate ID PFGE
type
1 64, M Cardiology 5% glucose solution, insulin,
ID, PMA, KCl
Aug 8, 2010 TZP Survived P. putida C
2 72, F Cardiology Normal saline Aug 8, 2010 TZP, CIP Survived P. putida C
3 76, M Neurology 5% glucose solution, insulin,
PMA, normal saline
Aug 25, 2010 AMC Survived P. fulva A
4 60, M Neurology 5% glucose solution, insulin,
BH, PMA, alprostadil
Sep 16, 2010 AMC Survived P. fulva A
5 91, M Gastrointestinal
disease
10% glucose solution, omeprazole,
glutathione, PMA
Oct 10, 2010 CXM,
cefmetazole
Survived P. fulva A
6 42, M Cardiac care unit 5% glucose solution, insulin,
ID, PMA, KCl
Apr 29, 2011 CSL Survived P. fulva E
7 71, M Cardiology 5% glucose solution, insulin, ID, PMA Aug 14, 2011 CSL, AZI Survived P. fulva B
8 52, F Cardiology 5% glucose solution, insulin, ID, PMA Aug 13, 2011 Cefminox Survived P. fulva A
9 70, M Cardiology 5% glucose solution, insulin, ID, PMA Aug 21, 2011 CSL, LEV Died P. fulva B
10 67, M Surgical ICU 5% glucose solution, KCl Aug 21, 2011 CSL Survived P. putida D
11 55, M Cardiology 5% glucose solution, insulin, ID, PMA Aug 22, 2011 CSL, oﬂoxacin Survived P. fulva B
12 58, M Cardiology 5% glucose solution, insulin, ID, PMA Sep 7, 2011 TZP, MOX Survived P. fulva A
13 71, M Neurology 5% glucose solution, insulin,
KCl, alprostadil
Sep 10, 2011 FOX Survived P. fulva A
14 48, F Gastrointestinal
disease
5% glucose solution, PMA Sep 10,2011 FOX Survived P. fulva A
15 68, F Cardiology 5% glucose solution, insulin, ID, PMA Sep 22, 2011 Cefmetazole Survived P. fulva A
16 62, M Surgical ICU Lactated Ringer’s, omeprazole Sep 25, 2011 FOX Survived P. putida D
17 81, M Cardiology 5% glucose solution, insulin, ID, PMA Dec 13, 2011 CSL Survived P. fulva B
18 55, M Cardiology 5% glucose solution, insulin, ID, PMA Sep 5, 2012 CSL, MOX Survived P. fulva F
19 33, M Cardiology 5% glucose solution, insulin, ID, PMA Sep 5, 2012 AMC Survived P. fulva B
20 72, F Cardiology 5% glucose solution, insulin, ID, PMA Sep 9, 2012 CSL, MOX Survived P. fulva F
PFGE, pulsed-ﬁeld gel electrophoresis; M, male; F, female; ICU, intensive care unit; ID, isosorbide dinitrate; PMA, potassium magnesium aspartate; TZP, piperacillin–
tazobactam; CIP, ciproﬂoxacin; AMC, amoxicillin–clavulanic acid; BH, buﬂomedil hydrochloride; CXM, cefuroxime; CSL, cefoperazone–sulbactam; AZI, azithromycin; LEV,
levoﬂoxacin; MOX, moxiﬂoxacin; FOX, cefoxitin.
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Culturing of the unopened solutions in their original packaging
produced no growth during the outbreak period in 2012. Intrinsic
contamination was ruled out by negative culture of the unopened
stock solutions used for preparing the compounded solutions. A
total of 25 intravenous ﬂuids used by patients in the cardiology
ward were cultured; the compounded solution (5% glucose
solution containing insulin, isosorbide dinitrate, and potassium
magnesium aspartate) used by patient 18 tested positive for P.
fulva, while the rest showed negative culture results.
PFGE analysis of the 23 strains revealed six PFGE types, as show
in Figure 1 (the banding patterns are designated PFGE A to F).
Isolates from eight patients in different wards over a 3-year period
and an environmental surface isolate from the bench of the
hospital pharmacy shared the same PFGE pattern (type A),Figure 1. PFGE of Pseudomonas fulva and Pseudomonas putida isolates obtained during Au
from patients in different wards; S1: isolate from a pharmacy bench surface; S2: isolate
placed in the pharmacy. First lane on the left hand side is the molecular weight markesuggesting a clonally related origin. Two isolates from patient
18 in the cardiology ward were identiﬁed from different sites
(peripheral blood and used solution sample), and showed the same
PFGE type (type F) to that of the environmental isolate from the
basket in the hospital pharmacy center, also indicating clonal
relatedness. Therefore, the compounded solution (5% glucose
solution containing insulin, isosorbide dinitrate, and potassium
magnesium aspartate) was strongly suspected as the source of the
outbreak, having become contaminated when it was prepared or
when administered to that patient.
4. Discussion
Outbreaks of bloodstream infection caused by various agents
linked to contaminated infusions and medications are wellgust 2010 to September 2012, Beijing, China. Numbers 1–20: bloodstream isolates
 from in-use solution; S3: isolate from a tray on which the prepared solution was
r.
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the manipulation of multi-dose vials.14,15 The preparation of drug
products can lead to an outbreak if stringent quality-control
standards are not implemented.16 In China, medications are
reconstituted for the special needs of the patients in the hospital
pharmacy center. In the present case, the major cause of the
outbreak was probably P. fulva in the environment, which was
introduced into the mixed ﬂuids either during manipulation of the
solution in the hospital pharmacy or during administration to
multiple patients in the hospital wards. According to PFGE, type A
found in the environment showed an identical pattern to that
isolated from the patients (patients 3, 4, 5, 8, 12, 13, 14, and 15) in
three different wards; type F found in the environment had an
identical pattern to the patient 18 clinical isolate and the isolate
from the used compounded solution. In most outbreaks, the source
of the pathogens responsible is difﬁcult to identify by environ-
mental surveillance, even if the bacteria are isolated from patients
or the environment.17,18 Fortunately, the present investigation was
able to establish the link between the outbreak and the
environmental pathogen because the hospital infection control
team traced the solution administered to each patient and cultured
the unused solutions effectively. Therefore, we were able to
identify patients who had received the contaminated solutions.
The ﬁndings from this investigation indicate the risks of using
intravenous formulations of medications.
Another ﬁnding in the current study was that the hospital
pharmacy prepares compounded solutions for more than 30 wards
within our hospital every day. However, the outbreak involved
only ﬁve different wards over a 3-year period and most of the cases
were detected in the cardiology ward. After reviewing common
exposures for case-patients, we focused on intravenous infusions,
medications, case-patient clinical signs, treatments, and outcomes.
One possible explanation is the fact that in the cardiology ward,
most patients required the use of venous catheters for more
prolonged periods of time compared to patients in the other wards.
It appears that a prolonged injection time may contribute to the
development of bacteremia in these patients.
The outbreak seemed to be under control from September 2012
after an intensiﬁcation of infection control practices. Up to the end
of October 2013, no new P. fulva or P. putida isolates had been
detected in our hospital. One possible explanation for the success
may be the prompt recognition of the outbreak, the infection
control intervention, and the early administration of antimicrobial
therapy. Another possibility may be the low human pathogenicity
of P. fulva and P. putida. However, the outbreak lasted for 3 years,
suggesting the potential for long-lasting persistence of this
microorganism and the possible role of P. fulva and P. putida as
a long-lasting reservoir in the hospital environment. As these
pathogens cannot be eradicated from the hospital environment,
constant infection control measures are needed in order to prevent
future nosocomial infections.
Regarding the hospital pharmacy, quality assurance/quality
control of the pharmacy was implemented routinely before,
during, and after the outbreak in accordance with hospital
regulations. In order to avoid a similar incidence in the future,
several new practices and control measures have been put in place,
such as increasing staff awareness of hand washing, more frequent
cleaning of environmental surfaces with disinfectants and
sterilization of the working environment, modifying the prepara-
tion methods of the reconstituted solutions to ensure minimum
handling of the solutions, and altering the IV regimen in order to
shorten the infusion time. To facilitate the efﬁcient identiﬁcation of
possible contaminated compounded solutions, sterility testing of
the reconstituted solutions is performed regularly.
A limitation of this report is that we only identiﬁed the
contaminated intravenous compounded solutions as the source ofnosocomial P. fulva bacteremia during the year 2012. Although the
outbreaks in 2010 and 2011 were only investigated retrospective-
ly, they shared similarities (same pathogen, same season, and same
wards) with that in 2012; we could therefore reasonably
hypothesize that contaminated solutions might also have been
responsible for the outbreaks in the past years.
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